Basket

  Untick selected:   0
  1. A Phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for locally advance or metastatic colorectal cancer: final results of the pegfilgrastim and anti-VEGF evaluation study (PAVES)  / Salek T. .  Onkológia. - ISSN 1336-8176 . - Roč. 12, č. 5 (2017), s. 379  
    C 3069
    article

    article


  This site uses cookies to make them easier to browse. Learn more about how we use cookies.